NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full ...

An 18-year-old has revealed how she was tested for countless illnesses throughout 2024 until an unusual symptom exposed the ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

“We were surprised to discover that KMT could work synergistically with the IDH1 mutation to simultaneously target the ... including the Foundation for Metabolic Cancer Therapies, Children with Cancer ...

Doctors eventually discovered she had a type of glioma brain tumour called IDH1 mutation astrocytoma ... Sienna Barbara is 18 and has brain cancer. Picture: Supplied “After the seizure we ...

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.

The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

A young British woman who used to drink 12 cups of coffee a day and quit because of some caffeine withdrawal symptoms like ...

Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome Chondrosarcomas are rare cancers of cartilage with limited systemic therapy options. To identify potential ...